Abstract-The diagnosis of primary aldosteronism typically requires at least one confirmatory test. The fludrocortisone suppression test is generally accepted as a reliable confirmatory test, but it is cumbersome. Evidence from accuracy studies of the saline infusion test (SIT) and the captopril challenge test (CCT) has provided conflicting results. This prospective study aimed to evaluate the diagnostic accuracy of the SIT and CCT using fludrocortisone suppression test as the reference standard. One hundred thirty-five patients diagnosed with primary aldosteronism and 101 patients diagnosed with essential hypertension who completed the 3 confirmatory tests were included for the diagnostic accuracy analysis. 
P rimary aldosteronism (PA) is caused by adrenocortical lesions characterized by the autonomous secretion of aldosterone. It is a common cause of secondary hypertension, and its reported prevalence ranges from 5% to 20% in hypertensive patients. 1 PA can be classified into several subtypes, including aldosterone-producing adenoma, bilateral adrenal hyperplasia, unilateral adrenal hyperplasia, and glucocorticoid remediable aldosteronism. Patients with PA are at a higher risk of cardiovascular complications than those with essential hypertension (EH). 2 Therefore, accurate diagnosis and appropriate treatment are essential. The diagnosis of PA includes screening, confirmation, and subtype classification. The plasma aldosteronerenin ratio (ARR) has been widely used as a screening test, and patients who test positive are usually recommended to undergo at least one confirmatory test. When PA is confirmed, further tests are needed for subtype classification, such as adrenal computed tomography (CT) and bilateral adrenal venous sampling (AVS).
The Endocrine Society's clinical practice guideline recommend 4 confirmatory tests, including the fludrocortisone suppression test (FST), saline infusion test (SIT), captopril challenge test (CCT), and oral sodium loading. 3 Of these, FST is considered the most reliable for PA confirmation by some researchers, but it is cumbersome, difficult to perform, and relatively expensive, requiring hospital admission for several days. 4, 5 Evidence from accuracy studies of other confirmatory tests, including the SIT and CCT, has shown conflicting results.
Given the inconsistency of previous findings and the absence of definitive data to determine which confirmatory test is most accurate and feasible, guideline and consensus statements report that currently there is insufficient evidence to recommend any one confirmatory test over another. 3, 10, 11 In this prospective study, we aimed to evaluate the diagnostic accuracy of the SIT and CCT, using FST as the reference standard, in patients with a high risk for PA.
Methods

Reproducible Research Statement
Study protocol and statistical code are available from the author Q.L. Data set is not available.
Study Design and Participants
This study was conducted in the Department of Endocrinology, the First Affiliated Hospital of Chongqing Medical University, from November 2013 to September 2016. The Ethics Committee of the First Affiliated Hospital of Chongqing Medical University approved the protocol. Informed written consent was obtained from each participant.
Patients with a high risk for PA who were willing to participate in the study were recruited. The inclusion criteria and exclusion criteria are provided in the online-only Data Supplement.
Screening and Confirmatory Tests
For the screening test and the confirmatory tests, antihypertensive medication was withheld or changed according to the guideline. 3 Treatment with diuretics was withheld for at least 4 weeks. β-Blockers, angiotensin-converting enzyme inhibitors, and angiotensin-II receptor blockers were stopped for at least 2 weeks. Only the nondihydropyridine calcium channel blocker, terazosin, and doxazosin were allowed for uncontrolled hypertension. For screening, samples for plasma renin concentration (PRC) and plasma aldosterone concentration (PAC) were collected in the morning after the subjects were out of bed for at least 2 hours. ARR was calculated. The screening test was considered positive when ARR≥3.7 ng•dL
). 3 Patients who tested positive or who tested negative but PA was strongly suspected proceeded to the 3 confirmatory tests. For the remaining patients who screened negative, 1 in every 3 consecutive patients underwent the 3 confirmatory tests, which were performed on 3 separate days. SIT 3 : Patients stayed in the recumbent position for at least 1 hour before and during the infusion of 2 L of 0.9% saline over 4 hours, starting at 8:00 am. Blood samples for PRC, PAC, cortisol, and plasma potassium were drawn at time zero and after 4 hours. During the test, the patients remained fasted, and blood pressure and heart rate were closely monitored. CCT 3 : Patients received 50-mg captopril orally at 8:00 to 9:00 am after sitting or standing for at least 1 hour. Blood samples were drawn for the measurement of PRC and PAC at time zero and 2 hours after the challenge, with the patient remaining seated during this period.
FST 12 : Patients received 0.1-mg oral fludrocortisone every 6 hours for 4 days, together with slow-release KCl supplements to keep plasma K + levels close to 4.0 mmol/L, NaCl supplementation (30 mmol 3 times daily with meals), and sufficient dietary salt to maintain a urinary sodium excretion rate of at least 3 mmol/kg. On day 4, PAC and PRC were measured at 10:00 am with the patient in a seated position, and plasma cortisol was measured at 7:00 am and 10:00 am
Further Tests
Patients with a positive result in any confirmatory test underwent an enhanced adrenal CT scan. Patients willing to undergo adrenalectomy were submitted to AVS, and the criteria used to determine the lateralization of aldosterone hypersecretion were established according to guideline (details are provided in the online-only Data Supplement). 3 In patients with an onset of confirmed PA earlier than 20 years of age and in those with a family history of PA or strokes at a young age, genetic testing for glucocorticoid remediable aldosteronism by the long polymerase chain reaction technique 13 was performed. The dexamethasone suppression test and plasma metanephrines assays (using high-performance liquid chromatography method) were performed to confirm hypercortisolism and pheochromocytoma, respectively.
Diagnostic Criteria
The diagnosis of PA was established according to the FST criteria 12, 14 : when PAC is not suppressed to <8 ng/dL (220 pmol/L) on day 4, the diagnosis of PA should be considered. In addition, if AVS was performed despite a negative FST and demonstrated lateralization and led to unilateral adrenalectomy, such patients would be included in the PA group. For the diagnostic criteria of the subtypes of PA, details are provided in the online-only Data Supplement.
Biochemical Measurements
PRC and PAC were measured with automated chemiluminescence immunoassays (LIAISON; DiaSorin, Italy). Details are provided in the online-only Data Supplement.
Statistical Analysis
Data distributions were analyzed with the Kolmogorov-Smirnov test. Normally distributed variables were expressed as the mean±SD; variables with skewed distributions were expressed as the median (quartile range); and categorical variables were described as a percentage. Variables with skewed distributions were analyzed after natural logarithm transformation. Categorical variables were analyzed by the χ 2 test, and quantitative variables were analyzed by Student t test. SPSS 21 was used for statistical analysis. To assess the diagnostic accuracy of each confirmatory test, parameters including sensitivity, specificity, positive predictive value, negative predictive value, positive likelihood ratio, negative likelihood ratio, and area under the receiver-operator characteristics curve (AUC) were calculated by MedCalc software 8.1.1.0. P values < 0.05 (2-tailed) were considered statistically significant.
Results
Clinical Characteristics of the Subjects
Five hundred thirty-one hypertensive patients were enrolled. Ten patients were excluded because of malignancy (n=4), heart failure (n=3), and renal failure (n=3). Five hundred twenty-one patients completed ARR screening. The clinical characteristics of the 521 subjects are shown in Table S1 in the online-only Data Supplement. According to the protocol, 312 patients were eligible for confirmatory tests after ARR screening. Among the 312 patients, 32 patients were excluded: 13 patients were diagnosed with other causes of secondary hypertension; 13 patients withdrew because of personal reasons; and 6 patients revealed typical PA characteristics (spontaneous hypokalemia, undetectable renin, and plasma aldosterone concentrations higher than 20 ng/dL) and declined further confirmation testing. Two hundred eighty patients completed the CCT. Among them, 13 patients who could not undergo the SIT attributable to severe uncontrolled hypertension and 31 patients who refused to take the FST were excluded (Figure 1 ).
Finally, 236 patients completed the 3 tests, and 235 patients were classified by the FST criteria, including 134 with PA and 101 with EH. One patient with a negative FST result showed an adrenal nodule on a CT scan and underwent unilateral adrenalectomy; the curative effect during follow-up confirmed the diagnosis of PA. Therefore, 135 patients were ultimately diagnosed with PA, and 101 were diagnosed with EH. No significant differences were observed between the PA and EH groups in terms of sex and age. Patients with PA had higher systolic blood pressure and lower serum potassium compared with patients in the the EH group. The characteristics of the 236 subjects are shown in Table 1 .
Seventy-six patients who were preliminarily considered as unilateral PA had unilateral adrenalectomy. According to the consensus criteria for outcomes after adrenalectomy for unilateral PA, 15 the proportions of unilateral PA patients with clinical complete, partial, and absent success were 56.6%, 40.8%, and 2.6%, respectively, and the proportions of patients with biochemical complete, partial, and absent success were 93.4%, 5.3%, and 1.3%, respectively. Because only complete biochemical success reflects the correct diagnosis, 15 71 PA patients, including 65 patients with aldosterone-producing Table S2 .
Diagnostic Accuracy of the SIT
PAC and PRC values before and after the 3 confirmatory tests are shown in Table 2 . Using PAC post-SIT to confirm PA, the receiver-operator characteristics curve analysis showed that the AUC of the SIT was 0.96 (95% confidence interval [CI], 0.92-0.98; Figure 2 ). When the cutoff for PAC post-SIT was set at 10 ng/dL, the SIT showed a specificity of 0.96 (95% CI, 0.90-0.99) and a sensitivity of 0.81 (95% CI, 0.73-0.87), so 26 out of 135 PA patients (19%) would be missed. When the PAC post-SIT cutoff was 5 ng/dL, the number of missed PA patients was reduced to 6, but 30 EH patients (30%) were misdiagnosed with PA. A cutoff of 8.0 ng/dL provided the best compromise between sensitivity and specificity, resulting in a positive predictive value of 0.94 (95% CI, 0.88-0.97) and a negative predictive value of 0.82 (95% CI, 0.74-0.89; Table 3 ).
Diagnostic Accuracy of the CCT
According to the Endocrine Society Clinical Practice Guideline, 3 a PAC suppression percentage in the CCT (defined as [PAC pre-CCT−PAC post-CCT]/PAC pre-CCT) <30% is recommended to confirm PA. Using this method, the CCT had an AUC of 0.71 (95% CI, 0.65-0.77; Figure 2 ), a sensitivity of 0.78 (95% CI, 0.70-0.85), and a specificity of 0.52 (95% CI, 0.42-0.63; Table S3 ). However, when the PAC suppression percentage in the CCT was substituted by PAC post-CCT, the AUC of the CCT increased to 0.96 (95% CI, 0.92-0.98), comparable to that of the SIT (Figure 2) .
The accuracy of the CCT was further analyzed at different cutoffs of PAC post-CCT (Table 3) . A PAC post-CCT of 13 ng/ dL displayed a high specificity of 0.95 (95% CI, 0.89-0.98), but 22 PA patients would be missed. When PAC post-CCT was lowered to 8 ng/dL, the number of missed PA patients was reduced to 7, but the number of patients misdiagnosed as EH increased to 23. Considering both sensitivity and specificity, an optimal cutoff of PAC post-CCT was set at 11 ng/dL, resulting in a sensitivity of 0.90 (95% CI, 0.84-0.95) and a specificity of 0.90 (95% CI, 0.83-0.95), showing similar diagnostic accuracy to the SIT (with the PAC post-SIT cutoff set at 8 ng/dL; P=0.192 for sensitivity; P=0.551 for specificity).
According to the Japan Endocrine Society, ARR post-CCT can also be used for PA confirmation. 10 Table S3 ).
Exploratory Analysis in the Unilateral PA Subgroup
The results from the unilateral PA (aldosterone-producing adenoma plus unilateral adrenal hyperplasia) subgroup are shown in Table S4 . Similarly, in the unilateral PA subgroup, using the PAC suppression percentage to confirm PA, the CCT had an AUC of 0.75 (CI, 0.70-0.81), but when using PAC post-CCT, the AUC of CCT increased to 0.98 (CI, 0.95-1.00), which was comparable to that of the SIT (0.98; 95% CI, 0.95-1.00).
Because FST is not a perfect tool for the diagnosis of PA, the diagnostic performance of the 3 tests has been analyzed in patients with unilateral PA, and the results showed similar sensitivity among the 3 tests (Table S5) .
Discussion
The FST is regarded as the most reliable confirmatory test for PA diagnosis by some researchers. 4, 5 However, the FST is cumbersome and time-consuming, and it is seldom used as the reference test when the accuracy of other confirmatory tests was evaluated. To our knowledge, this is the first prospective study using the FST as the reference test to simultaneously assess the diagnostic accuracy of the SIT and CCT in patients with a high risk for PA. There are 2 main findings in this study: first, both the CCT and SIT had good accuracy in PA confirmation and served as reasonable alternatives to the more expensive and complex FST. However, considering the advantages of the CCT, including safety, cost-effectiveness, and feasibility to perform in outpatients, and the disadvantages of the SIT (eg, risk of fluid retention), the CCT may provide a better test alternative. Second, the diagnostic accuracy of the CCT varied with different methods of interpretation, and PAC post-CCT is a better approach compared with the PAC suppression percentage. These findings add considerable data to the available information on current confirmatory approaches for PA. Our results challenge the current recommendation of choosing confirmatory tests with no priority and the approach of adopting the PAC suppression percentage to interpret the results of the CCT.
The sensitivity and specificity of the CCT vary greatly across previous studies. 8, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] This may be because of the different doses of captopril (25 or 50 mg), the timing of blood draws (60, 90, or 120 minutes after captopril administration), interpretation of the results (PAC suppression percentage, PAC post-CCT, or ARR post-CCT), and the number of subjects included. Although the CCT has obvious advantages such as easy execution and no risk of fluid overload, reports of false-negative and equivocal results challenge its test performance. 9, 17, 23 Here, in our prospective study, high accuracy of the CCT was demonstrated when the FST was used as the reference standard. According to our results, PAC post-CCT levels >13 ng/dL indicate probable PA, and PAC post-CCT levels <8 ng/dL make the diagnosis of PA unlikely.
The Endocrine Society guideline recommend that a suppression percentage <30% in the CCT can confirm PA, 3 which has not been verified according to our literature review. In our study, a suppression percentage of 30% as the cutoff caused many hypertensive patients to be misdiagnosed. Our study also enrolled 20 healthy volunteers to complete the 3 confirmatory tests (data not shown). Surprisingly, 25% of the healthy volunteers (5 out of 20) showed positive CCT results using this cutoff value. Several groups prefer the use of ARR post-CCT, [16] [17] [18] [19] [20] 23, 24 which showed acceptable diagnostic accuracy in our study. However, we found that the diagnostic performance of ARR post-CCT was inferior to that of PAC post-CCT, which is consistent with the study by Kim et al. 8 Taken together, our data support using PAC post-CCT for diagnostic interpretation.
Several previous studies have evaluated the accuracy of the SIT, 6, 16, 20, 21, [27] [28] [29] [30] but only a few studies have directly compared the reliability of the SIT to the FST. One multicenter study conducted by Mulatero et al, 6 including 98 hypertensive patients, noted that the SIT (using a PAC post-SIT of 5 ng/dL) led to a correct diagnosis in most cases (88%), and no patient ultimately diagnosed with aldosterone-producing adenoma was misdiagnosed by the SIT. Similarly, in our study, when the cutoff of PAC post-SIT was set at 5 ng/dL, a correct diagnosis was determined in 200 out of 236 patients (85%). Another study included 155 hypertensive patients who underwent the SIT or the FST, or both. 29 In an analysis of 33 patients (17 patients with PA and 16 with EH) who underwent both the SIT and FST, the authors reported a sensitivity of 82.5% and a specificity of 91.8% for the SIT, which is similar to the results in our prospective study but with a lower PAC cutoff at 3.15 ng/dL. In contrast, a study conducted by Ahmed et al 7 reported a low sensitivity for the SIT in the supine position. In their study, only 8 out of 24 PA patients (23 PA cases confirmed by PAC post-FST >6 ng/dL) tested positive by the SIT (PAC post-SIT >5 ng/dL). With only 3 patients who tested negative for PA by the FST, the authors were unable to estimate the specificity of the SIT. The reason for the different results is unclear, but the PAC pre-SIT levels of PA patients in the study by Ahmed et al (ranging from 2.70 to 61.70 ng/dL, with a median of 7.7 ng/dL) were considerably lower than those in our study (ranging from 5.89 to 241.8 ng/dL, with a median of 28.10 ng/dL). It is worth mentioning that our study used a higher cutoff of 8 ng/dL for the FST compared with the cutoff reported in other studies. 6, 7, 29 The divergence in cutoff values may be associated with the assay and technique used for aldosterone measurement. 31 Our study has some important strengths. First, it was prospectively designed, and the procedures of screening and confirmation were standardized according to the guideline. Second, this study included subjects who completed 3 tests, revealing not only the diagnostic accuracy of the SIT and CCT compared with the FST but also the differences in performance between the SIT and the CCT. This study also has some limitations. First, this study used the FST as the reference standard even though the FST has never been verified as a gold standard for PA, which may have biased the data interpretation. Second, the AVS rate was relatively low in our study. Only 75 PA patients had AVS, with a success rate of 79%. Nine patients with bilateral adrenal hyperplasia diagnosed according to normal adrenal CT results rather than AVS, and they could have been erroneously subtyped because a microadenoma may not be detected by CT scanning. Because some patients could not be accurately subtyped, the results from the exploratory subgroup analysis should be interpreted with caution. Third, this study was conducted in a single tertiary hospital center and in a highly selected population (with a high prevalence of hypokalemia and adrenal masses). Therefore, our results need to be tested in a broader population. Besides, in view of the fact that 18% of the EH-categorized patients had a history of hypokalemia, it does leave open the possibility that a significant number could have had PA that was missed by using FST as our reference standard.
Perspectives
In conclusion, the CCT and SIT are reasonably good alternatives to the more expensive and complex FST. On the basis of the advantages and disadvantages of the CCT and SIT, the former may be a better alternative. Although the Endocrine Society guideline recommend a PAC suppression percentage >30% for diagnostic interpretation in the CCT, our results showed that PAC post-CCT is a better approach. Therefore, when interpreting the results of the CCT, PAC post-CCT is recommended.
